BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 20254Q 2024 Total Revenues of $747 million (+16$2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y)Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Calif., Feb. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced fina ...